Location History:
- New Palastine, IN (US) (2004)
- New Palestine, IN (US) (2003 - 2011)
Company Filing History:
5 out of 4,442 
2 out of 35 
1 out of 202 Years Active: 2003-2011
Title: Innovator Spotlight: Steven Scott Henry - Pioneering mGlu5 Antagonists and Alzheimer's Disease Treatments
Introduction:
In the world of innovation and patent contributions, few inventors have made as significant an impact as Steven Scott Henry. Hailing from New Palestine, IN in the United States, Henry has an impressive portfolio of 15 patents to his name. This article delves into his latest patents, career highlights, collaborative endeavors, and the contributions he has made to the field of biomedical research.
Latest Patents:
Henry's most recent patents showcase his expertise in developing pyridyl derivatives as mGlu5 antagonists. These compounds, represented by formula (I), have shown promising potential in the treatment and prevention of disorders remedied by antagonism of the mGlu5 receptor. With Ar as phenyl or naphthyl, each substitutable by various additional groups, these compounds open up new avenues for therapeutic intervention.
Another notable patent from Henry focuses on cycloalkyl, lactam, lactone, and related compounds. These compounds inhibit β-amyloid peptide release and synthesis, offering potential therapeutic applications in the treatment of Alzheimer's disease. The invention also encompasses pharmaceutical compositions containing these compounds and methods for both prophylactic and therapeutic treatment of Alzheimer's disease.
Career Highlights:
Throughout his illustrious career, Henry has demonstrated his commitment to advancing biomedical research and pharmaceutical innovation. His work spans across several influential organizations, including Eli Lilly and Company. Collaborating with renowned industry leaders, Henry carved a path of expertise in target-specific therapeutics, particularly concerning neurological disorders.
Collaborations:
Steven Scott Henry has had the privilege of working alongside esteemed colleagues in his field, including Thomas Charles Britton and Bruce Anthony Dressman. These collaborations likely contributed to the advancements made in the development of mGlu5 antagonists and Alzheimer's disease treatments. The exchange of ideas and expertise among these inventors may have played a pivotal role in the success of their patent applications and subsequent research developments.
Conclusion:
Steven Scott Henry's contributions in the realm of innovations and patents have significantly impacted the field of biomedical research. His latest patents concerning mGlu5 antagonists and compounds for the treatment of Alzheimer's disease highlight his dedication to improving human health. As an integral part of influential companies like Eli Lilly and Company, Henry's expertise has been instrumental in paving the way for advancements in pharmaceutical sciences. We look forward to further breakthroughs from this exceptional inventor, as he continues to make invaluable contributions to the field of innovation and patents.
Please note that the detailed patent descriptions provided have been simplified for the purpose of this article and may not encompass all technical nuances present in the original patent documentation. For more in-depth information, it is recommended to refer to the original patent filings and associated documents.
Inventor’s Patent Attorneys refers to legal professionals with specialized expertise in representing inventors throughout the patent process. These attorneys assist inventors in navigating the complexities of patent law, including filing patent applications, conducting patent searches, and protecting intellectual property rights. They play a crucial role in helping inventors secure patents for their innovative creations.